{"product_id":"convatecgroup-bcg-matrix","title":"Convatec Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eConvatec Group’s BCG Matrix preview highlights where core product lines likely sit across Stars, Cash Cows, Dogs, and Question Marks amid evolving wound care and ostomy markets; strategic shifts and portfolio pruning are increasingly pivotal. This sneak peek shows trends but not the full quadrant-by-quadrant evidence and actionable moves—purchase the complete BCG Matrix for a detailed Word report and an Excel summary with data-backed placements, tailored recommendations, and a ready-to-use roadmap for capital allocation and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfusion Care for Diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025 Convatec leads global infusion sets for insulin pumps, supplying ~35% share and benefiting from the automated insulin delivery market growing ~18% CAGR (2020–2025) to $6.2B in 2025.\u003c\/p\u003e\n\u003cp\u003eStrong partnerships with Tandem Diabetes Care and Medtronic drive \u0026gt;40% of unit sales, keeping this business in the Stars quadrant with high market share and high growth.\u003c\/p\u003e\n\u003cp\u003eConvatec’s continued R\u0026amp;D spend (~£60m in 2024, ~5% of group sales) on next‑gen extended‑wear sets supports pricing power and positions the unit as a primary revenue growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Wound Care Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-Triad Life Sciences integration, Convatec Group’s Advanced Wound Care Biologics sits as a Star in the BCG matrix, driving ~£220m in 2024 revenue (≈15% of group) with mid-20% CAGR in US biologics wound segment since 2021.\u003c\/p\u003e\n\u003cp\u003eThese premium-priced biologics treat complex chronic wounds and surgical sites, achieving ASPs 30–50% above standard dressings and 60% gross margins in 2024 US sales.\u003c\/p\u003e\n\u003cp\u003eConvatec invested \u0026gt;£60m in clinical trials and R\u0026amp;D in 2024 to defend share vs. emerging competitors and aims for double-digit market share in US regenerative wound care by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQUACEL Ag+ Extra Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAQUACEL Ag+ Extra is a Star for Convatec Group due to demonstrated clinical superiority in biofilm and infection control, supporting a leading antimicrobial dressing market share of ~28% globally as of 2025 and mid-teens CAGR in hospital adoption.\u003c\/p\u003e\n\u003cp\u003eConvatec’s steady line extensions with anti-biofilm tech drove a reported 2024 revenue for the AQUACEL family of ~£220m, up ~7% year-on-year, keeping pricing premia vs generics.\u003c\/p\u003e\n\u003cp\u003eThe category needs sustained marketing and clinical evidence investment—estimated 3–5% sales reinvestment—to defend against generic entrants and expand into APAC and LATAM where wound-care spend is growing \u0026gt;8% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec’s MyConvatec app and remote monitoring stack are Stars in the BCG Matrix: high-growth, high-share digital services boosting product stickiness and reducing churn; global app users exceeded 150,000 by Q4 2025 and remote monitoring pilots cut readmission rates by ~18% in 2024.\u003c\/p\u003e\n\u003cp\u003eThese tools modernize ostomy and wound care, give a tech-forward competitive edge, and by using analytics they secure leadership in digital therapeutics where market CAGR is ~20% (2023–30), supporting Convatec’s high-share position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150,000+ MyConvatec users (Q4 2025)\u003c\/li\u003e\n\u003cli\u003e18% lower readmissions in pilots (2024)\u003c\/li\u003e\n\u003cli\u003eDigital therapeutics market CAGR ~20% (2023–30)\u003c\/li\u003e\n\u003cli\u003eIncreases product stickiness and recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovations in Gentle Cath\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGentleCath (Convatec Group) sits in the BCG Matrix as a Star: Continuaence Care’s hydrophilic intermittent catheters grew double-digit; Convatec reported ~12% organic growth in Continence Care in FY2024 and raised US\/Europe market share to roughly 25–30% by prioritizing comfort and infection prevention.\u003c\/p\u003e\n\u003cp\u003eKeeping Star status needs ongoing R\u0026amp;D spend—Convatec increased R\u0026amp;D to ~4.5% of sales in 2024—to meet tighter FDA\/EMA rules and counter new competitor hydrophilic launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSegment: Continence Care—GentleCath\u003c\/li\u003e\n\u003cli\u003eGrowth: ~12% organic (FY2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: ~25–30% US\/Europe\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D: ~4.5% of sales (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: regulatory tightening, competitor launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec power players: Infusion sets, AQUACEL, Biologics, Digital \u0026amp; GentleCath growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec’s Stars: infusion sets (~35% share, $6.2B AID market by 2025), Advanced Wound Biologics (~£220m, mid-20% CAGR), AQUACEL Ag+ (~28% share, 60% gross margin), MyConvatec (150k users, 18% readmission cut), GentleCath (25–30% share, ~12% growth FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion sets\u003c\/td\u003e\n\u003ctd\u003e35% share, $6.2B(2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics\u003c\/td\u003e\n\u003ctd\u003e£220m, mid‑20% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQUACEL\u003c\/td\u003e\n\u003ctd\u003e28% share, 60% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e150k users, −18% readm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGentleCath\u003c\/td\u003e\n\u003ctd\u003e25–30% share, +12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Convatec: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest signals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix mapping Convatec units into quadrants for fast strategic decisions, export-ready for PowerPoint and C-level briefs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Ostomy Care Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec’s Standard Ostomy Care Systems, led by Natura and Esteem, occupy a dominant, stable share of the global traditional ostomy market—about 35% worldwide and ~40% in key Western markets as of 2025—driving predictable, recurring revenue from a loyal patient base that rarely switches once fitted. These mature products deliver high gross margins (around 60% historically) and low ongoing marketing spend, producing strong free cash flow: Convatec reported £300–350m annual operating cash from core legacy products in 2024. That cash funds high-growth R\u0026amp;D and newer product initiatives targeted at digital and advanced therapies, keeping the business balanced and scalable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHydrocolloid Wound Dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs the original pioneer of hydrocolloid technology, Convatec Group retains market leadership in this mature segment, with an estimated 28% global share of hydrocolloid dressings in 2024 and core gross margins around 62%.\u003c\/p\u003e\n\u003cp\u003eMarket volume growth for basic hydrocolloids was under 2% CAGR globally in 2020–2024, so these SKUs need little R\u0026amp;D or capex yet deliver outsized operating cash.\u003c\/p\u003e\n\u003cp\u003eManufacturing scale and brand recognition keep unit costs low (yearly opex per unit down ~14% since 2020), making hydrocolloids quintessential cash cows that fund Convatec’s higher-growth investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Care Hospital Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Critical Care Hospital Consumables portfolio—centered on fecal management systems and related products—serves a stable, low-growth acute care market, with hospital expenditure growth ~2% annually (2024 OECD hospital spending trends). Convatec’s established distribution and multi-year group purchasing organization contracts sustain a leading market share; the segment drove ~£420m of 2024 revenue and ~25% adjusted EBITDA margin. It requires minimal capex (CAPEX under 3% of sales in 2024), acting as a steady cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Continence Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Continence Accessories: basic urinary collection bags and accessories form a mature, high-volume segment for Convatec Group, accounting for an estimated 18% of 2024 product revenues (~£300m of FY2024 group sales), with market share above 25% in key EU and North American markets.\u003c\/p\u003e\n\u003cp\u003eLow tech disruption means focus on supply-chain and manufacturing efficiencies to lift gross margins; management reported 2024 gross margin expansion of ~120 basis points partly from these savings.\u003c\/p\u003e\n\u003cp\u003eCash flow from this segment is actively redirected to R\u0026amp;D and commercialization of intermittent catheter lines, which received ~£85m of incremental investment in 2024 to drive higher-growth innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh volume, mature product: ~18% revenue, ~25%+ market share\u003c\/li\u003e\n\u003cli\u003eStable tech profile: low disruption, margin lever via supply chain\u003c\/li\u003e\n\u003cli\u003e2024 impact: ~120 bps gross margin improvement from efficiencies\u003c\/li\u003e\n\u003cli\u003eCash redeployed: ~£85m invested into intermittent catheter R\u0026amp;D in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Foam Dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConvatec’s Standard Foam Dressings (ConvaMax and basic foam) sit in Cash Cows: mature foam market but strong clinical adoption; estimated 2024 foam segment share ~8–10% for Convatec, with recurring hospital and nursing-home use delivering steady EBITDA margins near 22%—supporting Advanced Wound Care R\u0026amp;D and commercial spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand: routine protocols in \u0026gt;60% of long-term care facilities\u003c\/li\u003e\n\u003cli\u003eEconomies of scale: production run-lengths cut COGS ~12% vs specialty lines\u003c\/li\u003e\n\u003cli\u003ePredictable revenue: contributes ~15% of AWC segment sales in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec’s high‑margin cash engines fund R\u0026amp;D and growth—£300–350m core cash, 60%+ GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec’s cash cows—Standard Ostomy (Natura\/Esteem), hydrocolloids, Critical Care consumables, continence accessories, and standard foams—generate predictable high-margin cash (core legacy operating cash ~£300–350m in 2024; hydrocolloid gross margin ~62%; Critical Care revenue ~£420m, adj. EBITDA ~25%), funding R\u0026amp;D (~£85m to catheters in 2024) and growth programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev\/Share\u003c\/th\u003e\n\u003cth\u003eGross\/EBITDA\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOstomy\u003c\/td\u003e\n\u003ctd\u003e~35% market; core cash £300–350m\u003c\/td\u003e\n\u003ctd\u003e~60% GM\u003c\/td\u003e\n\u003ctd\u003ePrimary cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHydrocolloid\u003c\/td\u003e\n\u003ctd\u003e28% global share\u003c\/td\u003e\n\u003ctd\u003e~62% GM\u003c\/td\u003e\n\u003ctd\u003eLow capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCritical Care\u003c\/td\u003e\n\u003ctd\u003e£420m\u003c\/td\u003e\n\u003ctd\u003e~25% EBITDA\u003c\/td\u003e\n\u003ctd\u003eStable cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eConvatec Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Convatec Group BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—fully formatted and ready for strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748279562617,"sku":"convatecgroup-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/convatecgroup-bcg-matrix.png?v=1772206967","url":"https:\/\/growthsharematrix.com\/products\/convatecgroup-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}